Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Femasys Inc. stock logo
FEMY
Femasys
$0.89
-4.4%
$1.06
$0.69
$1.80
$22.72M-2.62262,630 shs314,250 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.00
-3.8%
$1.92
$1.42
$12.33
$73.35M1.34625,562 shs615,670 shs
Nutriband Inc. stock logo
NTRB
Nutriband
$7.15
-5.9%
$5.99
$3.72
$11.78
$79.75M1.1180,868 shs32,014 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.81
-3.2%
$4.66
$4.01
$9.33
$79.10M1.32195,807 shs46,468 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Femasys Inc. stock logo
FEMY
Femasys
0.00%+11.16%-16.89%-43.36%-14.49%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-11.89%+2.56%-1.48%-78.90%
Nutriband Inc. stock logo
NTRB
Nutriband
0.00%-7.14%+27.68%+15.32%+17.79%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%-2.24%+3.22%+3.44%-11.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Femasys Inc. stock logo
FEMY
Femasys
3.0554 of 5 stars
3.53.00.00.03.12.50.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.9641 of 5 stars
3.32.00.04.33.30.01.3
Nutriband Inc. stock logo
NTRB
Nutriband
2.3098 of 5 stars
3.52.00.00.02.41.70.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.4429 of 5 stars
3.62.00.00.02.90.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Femasys Inc. stock logo
FEMY
Femasys
3.00
Buy$8.67874.55% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75387.50% Upside
Nutriband Inc. stock logo
NTRB
Nutriband
3.00
Buy$13.0081.82% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67142.55% Upside

Current Analyst Ratings Breakdown

Latest FEMY, NTRB, SRTS, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
5/13/2025
Femasys Inc. stock logo
FEMY
Femasys
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $6.00
5/9/2025
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/28/2025
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/19/2025
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $15.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Femasys Inc. stock logo
FEMY
Femasys
$1.70M13.37N/AN/A$0.85 per share1.05
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K259.09N/AN/A$5.16 per share0.39
Nutriband Inc. stock logo
NTRB
Nutriband
$2.40M33.25N/AN/A$0.73 per share9.79
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$39.49M2.00$0.05 per share96.29$2.98 per share1.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Femasys Inc. stock logo
FEMY
Femasys
-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%8/6/2025 (Estimated)
Nutriband Inc. stock logo
NTRB
Nutriband
-$5.49M-$0.90N/AN/AN/A-338.51%-54.49%-48.52%9/2/2025 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1012.0320.91N/A15.90%12.60%11.38%8/6/2025 (Estimated)

Latest FEMY, NTRB, SRTS, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2026
Nutriband Inc. stock logo
NTRB
Nutriband
-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 million
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/8/2025Q1 2025
Femasys Inc. stock logo
FEMY
Femasys
-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million
4/28/2025Q4 2025
Nutriband Inc. stock logo
NTRB
Nutriband
-$0.12-$0.18-$0.06-$0.51$0.71 million$0.64 million
3/27/2025Q4 2024
Femasys Inc. stock logo
FEMY
Femasys
-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Nutriband Inc. stock logo
NTRB
Nutriband
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Femasys Inc. stock logo
FEMY
Femasys
0.86
3.94
3.26
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
Nutriband Inc. stock logo
NTRB
Nutriband
0.01
4.96
4.83
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89

Institutional Ownership

CompanyInstitutional Ownership
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Nutriband Inc. stock logo
NTRB
Nutriband
19.70%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Femasys Inc. stock logo
FEMY
Femasys
11.54%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Nutriband Inc. stock logo
NTRB
Nutriband
54.09%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Femasys Inc. stock logo
FEMY
Femasys
3025.55 million20.08 millionNot Optionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
Nutriband Inc. stock logo
NTRB
Nutriband
1011.15 million5.10 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.45 million14.85 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Femasys stock logo

Femasys NASDAQ:FEMY

$0.89 -0.04 (-4.38%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.92 +0.03 (+2.89%)
As of 06/13/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.00 -0.08 (-3.85%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.04 +0.04 (+2.25%)
As of 06/13/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Nutriband stock logo

Nutriband NASDAQ:NTRB

$7.15 -0.45 (-5.92%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$6.90 -0.25 (-3.50%)
As of 06/13/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.81 -0.16 (-3.22%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$4.80 0.00 (-0.10%)
As of 06/13/2025 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.